European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019

Keyphrases

• Adjuvant Therapy 33%
• Anti-PD-1 Antibody 33%
• BRAF mutant 33%
• BRAF Wild-type 33%
• BRAF/MEK Inhibition 33%
• BRAFV600 66%
• Cancer Treatment 33%
• Consensus Building 100%
• CTLA-4 Inhibitors 33%
• Cutaneous Melanoma 66%
• Dermato-oncology 33%
• Distant Metastasis 33%
• European Associations 33%
• European Consensus 100%
• European Organizations 33%
• Expert Experience 33%
• First-line Therapy 33%
• Melanoma 100%
• Melanoma Detection 33%
• Melanoma Treatment 33%
• Multidisciplinary Experts 33%
• Mutational Status 33%
• Oncology Team 33%
• Pathologic Risk Factors 33%
• Patient with Tumor 33%
• Primary Resistance 33%
• Resistance to Immunotherapy 33%
• Safety Margin 33%
• Sentinel Lymph Node Dissection 33%
• Stage III-IV 100%
• Stage IV Melanoma 33%
• Staging Procedures 33%
• Survival Benefit 33%
• Systematic Literature Review 33%
• Systemic Therapy 33%
• Systemic Treatment 33%
• Therapeutic Decision-making 33%
• Trametinib 33%
• Treatment Lines 33%
• Treatment Update 100%
• Tumor Board 33%
• Tumor Thickness 33%

Medicine and Dentistry

• Adjuvant Therapy 33%
• Cancer Treatment 33%
• Cytotoxic T Lymphocyte Antigen 4 Antibody 33%
• Dabrafenib 33%
• Dermatology 33%
• Distant Metastasis 33%
• Immunotherapy 100%
• MEK Inhibitor 33%
• Melanoma 100%
• Melanoma Skin Cancer 66%
• Neoplasm 33%
• Oncology 66%
• Retroperitoneal Lymph Node Dissection 33%
• Sentinel Lymph Node 33%
• Systematic Review 33%
• Systemic Therapy 66%
• Trametinib 33%
• Tumor 33%